What is Treatment History?

Treatment history in leukemia encompasses all prior chemotherapy, targeted therapy, and other treatments received, along with the leukemia's response to those treatments. The response to initial treatment is one of the most important prognostic factors in leukemia—whether you achieved remission, how long remission lasted, and whether the leukemia was sensitive or resistant to treatment.

Treatment history defines whether you have "newly diagnosed," "relapsed," or "chemotherapy-resistant" disease, each with different prognosis and treatment approaches. It also guides selection of next-line therapies and clinical trial eligibility.

Treatment Response Categories

Treatment-Sensitive Disease

Definition: Leukemia responds to chemotherapy

Achieves complete remission (CR) with standard induction chemotherapy. Better prognosis and more treatment options available. Good response to clinical trial therapies.

Primary Chemotherapy Resistance

Definition: Fails to achieve CR with induction

Leukemia persists despite standard chemotherapy. Very poor prognosis (~5% 5-year survival). Requires alternative approaches including clinical trials, stem cell transplant, or novel targeted agents.

Relapsed Disease

Definition: Returns after initial remission

Initial response to treatment but leukemia recurs. Prognosis depends on length of remission. Early relapse (<6 months) worse than late relapse (>12 months). Second-line options based on prior therapy and sensitivity.

Relapse Timing and Prognosis

The timing of relapse is a critical prognostic factor:

Early relapse (<6 months): Very poor prognosis. Indicates chemotherapy-resistant disease. <10% 5-year survival with standard salvage therapy. High priority for clinical trials and stem cell transplant
Intermediate relapse (6-12 months): Poor prognosis. Some chemotherapy sensitivity but still resistant. 15-25% 5-year survival with salvage therapy
Late relapse (>12 months): Better prognosis. More chemotherapy-sensitive. 30-40% 5-year survival with second-line therapy. May re-respond to similar agents as initial treatment

Prior Treatment Impact

The specific chemotherapy received affects next-line options:

Previous anthracycline therapy: Limits use of additional anthracyclines due to cumulative cardiotoxicity
Prior intensive chemotherapy: May preclude additional intensive therapy; hypomethylating agents or clinical trials preferred
Prior targeted therapy (e.g., FLT3 inhibitor): Resistance mutations may have developed; next-generation agents or different targets needed
Stem cell transplant history: Relapse after transplant indicates very poor prognosis; requires novel approaches

Clinical Trial Importance

For relapsed/refractory leukemia, clinical trials are crucial:

Novel agents: Trials of new drugs not available outside research setting
Combinations: Testing synergistic combination approaches
Targeted therapy: For molecular subtypes (FLT3, TP53, etc.)
Better outcomes: Early-phase trials often provide best option for chemotherapy-resistant disease

Find Matching Trials →

Frequently Asked Questions

What does it mean if my leukemia is chemotherapy-resistant? ▼

Chemotherapy-resistant means your leukemia did not respond adequately to standard chemotherapy:

Primary resistance: Never achieved complete remission with initial chemotherapy
Relapsed/resistant: Initially responded but recurred quickly after treatment

This indicates more aggressive disease biology and requires alternative treatment approaches including clinical trials, targeted therapies, or stem cell transplant.

What is the difference between early and late relapse? ▼

Early versus late relapse is defined by how long after chemotherapy your leukemia returns:

Early relapse (<6 months): Returns very quickly. Indicates very chemotherapy-resistant disease. Poor prognosis
Late relapse (>12 months): Returns after long remission. Indicates more chemotherapy-sensitive disease. Better prognosis

Late relapse often responds better to second-line therapy, while early relapse requires novel approaches.

What are the treatment options for relapsed leukemia? ▼

Treatment options for relapsed leukemia include:

Salvage chemotherapy: Different chemotherapy regimens than initial treatment
Hypomethylating agents: Less toxic alternative for unfit patients
Targeted therapy: If molecular markers (FLT3, TP53) identified
Stem cell transplant: For fit patients who achieve second remission
Clinical trials: Often best option for chemotherapy-resistant disease

Your treatment plan depends on age, fitness, prior therapy, and disease characteristics.

How does treatment history affect clinical trial eligibility? ▼

Treatment history significantly affects clinical trial eligibility:

First-line trials: Enroll newly diagnosed leukemia patients
Relapsed/refractory trials: Target patients with prior treatment failure
Prior chemotherapy limits: Some trials exclude patients who received specific prior therapies
Salvage trials: Designed for chemotherapy-resistant disease

Your treatment history helps identify which trials are appropriate for you.

What is salvage chemotherapy? ▼

Salvage chemotherapy refers to second-line treatment for relapsed leukemia:

Different drug combinations than initial induction therapy
Designed for chemotherapy-resistant disease
Lower complete remission rates than initial induction (~30-40%)
Goal is to achieve second remission before stem cell transplant

Salvage regimens are more intensive than initial treatment and require hospitalization.

When should I consider clinical trials for relapsed leukemia? ▼

Clinical trials should be strongly considered for relapsed leukemia because:

Limited standard options: Salvage chemotherapy has poor success rates
Novel approaches: Trials test new drugs not available elsewhere
Better outcomes: Many relapsed patients benefit from novel therapies in trials
Survival extension: Trials often offer longer survival than standard salvage therapy

For early relapse or primary chemotherapy resistance, clinical trials are often your best option.

Treatment History & Resistance in Leukemia